Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>Events>This Event
  Events - April 2014


Biosimilars and Biobetters USA

07 Apr 2014 - 08 Apr 2014 - Iselin, NJ, USA



Bookmark and Share


Through a series of exciting panel discussions, presentations and workshops, delivered by true industry experts and players, this meeting will offer effective strategies and solutions for developing cost effective biosimilars for the future.

Read more:

After the phenomenal success of our Biosimilars and Biobetters event hosted in London in October, the SMi Group is delighted to announce the launch of the Biosimilars & Biobetters Conference in Iselin, New Jersey, USA, in April 2014. Registration is now open.

Through a series of exciting panel discussions, presentations and workshops, delivered by true industry experts and players, the Biosimilars and Biobetters USA conference will offer effective strategies and solutions for developing cost effective biosimilars for the future.

Event’s website: www.smi-online.co.uk/2014biosimilars_usa20.asp 

Benefits of attending:

-      Gain up to date insight into the regulatory landscape and how it is effecting the industry

-      Evaluate commercialization and development strategies to gain a competitive advantage 

-      Calculate possible revenue streams from biosimilar production

-      Discover what lessons have been learned so far and what the future holds 

-      Boost your industry knowledge and relationships by networking and learning from key industry and academic leaders

Key speakers include:

-      Dr Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals

-      Dr John Pakulski, Senior Director, and Head US Biopharmaceutical Regulatory Affairs, Sandoz

-      Rodeina Challand, Executive Director, Biosimilars Development, Scientific Affairs, PRA International

-      Dr Stanley (SeungSuh) Hong, President, Research and Development, Celltrion Inc.

-      Paul Ashton, President & CEO, pSivida

-      Peter Pitts, President, Center for Medicine in the Public Interest (Former FDA Associate Commissioner)

-      Douglas M. Long, Vice President, Industry Relations, IMS Health

-      Dr Rakesh Dixit, Vice President, Research and Development Head, Global Biologics Safety Assessment, MedImmune (AstraZeneca Biologics), and many others. 

Don’t miss a chance to visit 2 interactive post-conference workshops:

A.    Differentiation Strategies for the Generics Industry. Workshop Leader: Asa Cox, Founder & CEO, Generic Pharma 2.0

B.    Launching a Biosimilar in an Innovator v. Generic World. Workshop Leader: Kristie Kuhl, JD, Executive VP, Makovsky

For further information please contact Jonathan Collins on +44 (0)20 7827 6734 or email: pharma@smiconferences.co.uk  



Further information
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!